The gout medication colchicine will be tested in a large UK study looking into potential early-stage Covid-19 treatments and enrollment criteria was widened for the latest arm of the trial, University of Oxford researchers said on March 3.
Consumer advocacy group Public Citizen petitioned the FDA to pull Takeda’s gout treatment Uloric (febuxostat) off the market.
Addition of Biologic KRYSTEXXA® (pegloticase) Expands and Diversifies Horizon’s Orphan Business; Leverages Rheumatology Expertise and Infrastructure; Transaction Is Expected to Be Immediately Accretive to Adjusted EBITDA in 2016; Conference Call […]
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca (NYSE: AZN) today presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, results of its Phase III double-blind, multicenter, placebo-controlled trial CRYSTAL, investigating […]
